New Insights into Cholesterol Management: A Breakthrough Discovery

Heart disease, often exacerbated by high cholesterol levels, remains the foremost cause of mortality globally. Despite advancements in cholesterol-lowering therapies, many individuals still find it challenging to maintain optimal cholesterol levels. Additionally, some patients face side effects that complicate their medical treatment.

Discovery of a Novel Biological Pathway

Recent research from the University of California San Diego School of Medicine has uncovered a previously unknown biological pathway that elucidates the mechanisms by which high cholesterol diets impair the body’s ability to eliminate low-density lipoprotein (LDL) cholesterol. This discovery could potentially shed light on new therapeutic strategies for managing high cholesterol levels.

“For years, it has been established that diets rich in cholesterol diminish the liver’s capacity to clear cholesterol from blood circulation, but until now, the mechanisms behind this phenomenon remained elusive,” stated Dr. Alan Saltiel, the senior author of the study and professor of medicine at UC San Diego. “Our findings explain an essential part of this complex puzzle.”

The Role of The Liver in Cholesterol Regulation

The liver is integral to the regulation of cholesterol levels, acting as a filtering system that retrieves cholesterol from the bloodstream for processing. This process is facilitated by LDL receptors found on liver cells, which function akin to docking stations, capturing LDL cholesterol circulating in the blood for internal processing.

The quantity of LDL receptors present is crucial; a higher number allows the liver to clear more cholesterol effectively. This principle underlies the effectiveness of common cholesterol medications such as statins and PCSK9 inhibitors, which work by maintaining or increasing the availability of these receptors.

New Mechanism Discovered

Through experiments using both mice and human cells, researchers identified a previously unrecognized method affecting the liver’s LDL receptor availability. Over time, this mechanism progressively reduces the number of available LDL receptors, complicating the regulation of blood cholesterol levels.

This process initiates with a protein called Ral, which had been previously studied in relation to fat cells. The team found that a high-cholesterol diet activates Ral, triggering a cascade of events that ultimately leads to a deficit in LDL receptors. As Ral activity escalates, the number of receptors diminishes, hampering the liver’s ability to clear LDL cholesterol from circulation.

Further investigation revealed the involvement of an enzyme named cathepsin A (CTSA), which exacerbates the reduction of LDL receptors. When researchers employed a small molecule inhibitor targeting CTSA, they observed significant stabilization of LDL receptors and a marked decline in circulating LDL cholesterol levels in mouse models.

Potential for New Treatment Options

The implications of this discovery are profound, particularly as this new pathway diverges from those currently targeted by existing cholesterol medications. Such a distinction could lead to the development of new treatment options for patients who do not respond adequately to conventional treatments.

“There is a vital need for additional cholesterol-lowering therapies, especially for individuals who struggle to reach safe cholesterol levels with current medications,” Dr. Saltiel emphasized. “The pathway we’ve identified operates independently of the mechanisms targeted by existing drugs, offering a fresh avenue for exploration.”

Leveraging Existing Research for Potential Therapies

While identifying a new biological target usually marks the beginning of a long drug development journey, researchers might have a head start. An experimental drug aimed at inhibiting CTSA had previously been assessed as a potential treatment for heart failure. Though that project was suspended for strategic reasons, the drug has successfully completed Phase 1 clinical trials, affirming its safety in humans.

This prior research fortuitously positions the CTSA inhibitor for potential progression into Phase 2 clinical trials aimed at evaluating its efficacy against high cholesterol.

“Fortunately, we have an experimental drug that has already been validated for safety in humans readily available,” Dr. Saltiel noted. “We hope to proceed with a clinical trial to assess its effectiveness, which could provide patients with new treatment options sooner than typically anticipated.”

Conclusion

The recent study, published in the journal Nature, not only enhances our understanding of cholesterol metabolism but also holds potential for the development of innovative therapeutic strategies to combat high cholesterol, ultimately aiming to reduce the prevalence of heart disease.

Co-authors of this pivotal research include a diverse group of scientists from UC San Diego, UC San Francisco, the University of Texas Health Science Center at San Antonio, and the University of Utah, with funding support from the National Institutes of Health and an American Diabetes Association postdoctoral fellowship.